Clinical Trials in Arizona

Showing 3801-3820 of 16,770 trials

A Study to Evaluate the Safety and Efficacy of A2B395, an Allogeneic Logic-gated CAR T, in Participants With Solid Tumors That Express EGFR and Have Lost HLA-A*02 Expression

NCT06682793

The goal of this study is to test A2B395, an allogeneic logic-gated Tmod™ CAR T-cell product in subjects with solid tumors including colorectal cancer (CRC), non-small cell lung cancer (NSCLC), head and neck squamous cell carcinoma (HNSCC), triple-negative breast cancer (TNBC), renal cell carcinoma (RCC) and other solid tumors that express EGFR and have lost HLA-A\*02 expression. The main questions this study aims to answer are: * Phase 1: What is the recommended dose of A2B395 that is safe for patients * Phase 2: Does the recommended dose of A2B395 kill the solid tumor cells and protect the patient's healthy cells Participants will be required to perform study procedures and assessments, and will also receive the following study treatments: * Enrollment in BASECAMP-1 (NCT04981119) * Preconditioning lymphodepletion (PCLD) regimen * A2B395 Tmod CAR T cells at the assigned dose

Solid Tumor, AdultColorectal CancerNon-Small Cell Lung+14 more

A2 Biotherapeutics Inc.240 participantsStarted May 2025

Gilbert, Arizona, United States • La Jolla, California, United States • Los Angeles, California, United States +7 more locations

RECRUITINGPhase 442 miles

Effectiveness and Tolerability of Zavegepant for Acute Migraine Treatment Among Those Using CGRP Targeting Preventive Medications

NCT06401642

Zavegepant (Zavzpret) is approved for the acute treatment of migraine with or without aura in the US. The purpose of this study is to investigate the effectiveness and tolerability of zavegepant for the acute treatment of migraine attacks amongst participants who are using calcitonin gene-related peptide (CGRP) migraine preventive treatments.

Migraine

Mayo Clinic200 participantsStarted Mar 2024

Phoenix, Arizona, United States

A Study to Evaluate the Safety and Efficacy of A2B395, an Allogeneic Logic-gated CAR T, in Participants With Solid Tumors That Express EGFR and Have Lost HLA-A*02 Expression

Effectiveness and Tolerability of Zavegepant for Acute Migraine Treatment Among Those Using CGRP Targeting Preventive Medications

Find Trials by Condition in Arizona

A Trial of Centanafadine Efficacy, Safety, and Tolerability in Adult Subjects With Binge Eating Disorder

First-in-Human Study of OKI-219 in Advanced Solid Tumors and Advanced Breast Cancer

Study of an Live-Attenuated Respiratory Syncytial Virus Vaccine in Infants and Toddlers

S1702 Isatuximab in Treating Patients With Relapsed or Refractory Primary Amyloidosis

Study With Quadrivalent Recombinant Influenza Vaccine (RIV4) Compared With Egg-Based Quadrivalent Influenza Vaccine (IIV4) in Participants Aged 3 to 8 Years

OCS DCD Heart + CAP Continued Follow-Up

Phase 1 Trial in Patients With Human Papillomavirus (HPV)-Associated Cancer

FebriDx® Method Comparison Study Protocol

A Prospective, US-based Study Assessing Mogamulizumab-associated Rash in Patients Diagnosed With Mycosis Fungoides or Sezary Syndrome and Treated With Standard of Care Mogamulizumab

A Phase 2 Study of YA-101 in Patients With Multiple System Atrophy

Study to Evaluate the Efficacy & Safety of the INTERCEPT Blood System for RBCs in Complex Cardiac Surgery Patients

A Study of LM-24C5 For Advanced Solid Tumors

Examining Distinct Immunophenotypes to Validate and Enhance Rational Treatment in Systemic Lupus

Omalizumab as Monotherapy and as Adjunct Therapy to Multi-Allergen OIT in Food Allergic Participants

PRI-VENT FSGS: Preemptive Rituximab to Prevent Recurrent Focal Segmental Glomerulosclerosis Post-Transplant

OCS-01 in Treating Inflammation and Pain in Post-cataract Patients

A Study of Belrestotug Plus Dostarlimab Compared With Placebo Plus Pembrolizumab in Previously Untreated Participants With Programmed Death Ligand 1 (PD-L1) High Non-small-cell Lung Cancer (NSCLC)

PLAN Intervention to Enhance Engagement of Latino Cancer Patients in Advanced Care Planning